Raphaël Serreau (MD, PhD,
Abstract
We studied ibuprofen and ketoprofen, drugs of the class of NSAIDs (profen) at risk during pregnancy. We performed the assays in colostral milk and mature breast milk to verify its compatibility during breastfeeding. The study included 20 breastfeeding mothers, treated orally by a minimum of 3 x 200 mg tablets of ibuprofen in order to reach steady state at least on the 7th day after the delivery. Ibuprofen half-life (t1/2) is previously documented in the literature 114 minutes21. Steady state concentration is achieved when ibuprofen is administered at a constant rate (5 x t1/2 ~ 10 hours), at a minimum of 3 tablets/day of 200 mg ibuprofen. Women included in our study were among those who seek information on the compatibility of ibuprofen and breastfeeding by contacting the Medic-Al network. Women below 18 years of age and/or treated by naproxen and/or who have not given their informed written consent were excluded. This study took place from the 1st of January 2011 till the 30th of September 2012. We want to offer breast milk as a occupational medicine health matrix that would be suitable for monitoring the effects of toxins as endocrine disruptors. A network of pharmacologists and perinatology toxicologists should make it possible to optimize the pursuit of knowledge in this still little studied field. For this purpose, the “PARADICT-O” Department of Preventive Medicine was created on January 28, 2018 in Orleans to continue the pharmacological research activities set up with the “Médic-Al” network in Paris.